Severity of COVID-19 in children with cancer : Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project

BACKGROUND: Children with cancer are frequently immunocompromised. While children are generally thought to be at less risk of severe SARS-CoV-2 infection than adults, comprehensive population-based evidence for the risk in children with cancer is unavailable. We aimed to produce evidence of the incidence and outcomes from SARS-CoV-2 in children with cancer attending all hospitals treating this population across the UK. METHODS: Retrospective and prospective observational study of all children in the UK under 16 diagnosed with cancer through data collection from all hospitals providing cancer care to this population. Eligible patients tested positive for SARS-CoV-2 on reverse transcription polymerase chain reaction (RT-PCR). The primary end-point was death, discharge or end of active care for COVID-19 for those remaining in hospital. RESULTS: Between 12 March 2020 and 31 July 2020, 54 cases were identified: 15 (28%) were asymptomatic, 34 (63%) had mild infections and 5 (10%) moderate, severe or critical infections. No patients died and only three patients required intensive care support due to COVID-19. Estimated incidence of hospital identified SARS-CoV-2 infection in children with cancer under 16 was 3%. CONCLUSIONS: Children with cancer with SARS-CoV-2 infection do not appear at increased risk of severe infection compared to the general paediatric population. This is reassuring and supports the continued delivery of standard treatment

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

Purpose: People living with cancer and haematological malignancies are at increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus third dose vaccine boosters are proposed to boost waning immune responses in immunocompromised individuals and increase coronavirus protection; however, their effectiveness has not yet been systematically evaluated. Methods: This study is a population-scale real-world evaluation of the United Kingdom’s third dose vaccine booster programme for cancer patients from 8th December 2020 to 7th December 2021. The cancer cohort comprises individuals from Public Health England’s national cancer dataset, excluding individuals less than 18 years. A test-negative case-control design was used to assess third dose booster vaccine effectiveness. Multivariable logistic regression models were fitted to compare risk in the cancer cohort relative to the general population. Results: The cancer cohort comprised of 2,258,553 tests from 361,098 individuals. Third dose boosters were evaluated by reference to 87,039,743 polymerase chain reaction (PCR) coronavirus tests. Vaccine effectiveness against breakthrough infections, symptomatic infections, coronavirus hospitalisation and death in cancer patients were 59.1%, 62.8%, 80.5% and 94.5% respectively. Lower vaccine effectiveness was associated with a cancer diagnosis within 12 months, lymphoma, recent systemic anti-cancer therapy (SACT) or radiotherapy. Lymphoma patients had low levels of protection from symptomatic disease. In spite of third dose boosters, following multivariable adjustment, individuals with cancer remain at increased risk of coronavirus hospitalisation and death compared to the population control (OR 3.38, 3.01 respectively. p<0.001 for both). Conclusions: Third dose boosters are effective for most individuals with cancer, increasing protection from coronavirus. However, their effectiveness is heterogenous, and lower than the general population. Many patients with cancer will remain at increased risk of coronavirus infections, even after 3 doses. In the case of patients with lymphoma, there is a particularly strong disparity of vaccine effectiveness against breakthrough infection and severe disease. Breakthrough infections will disrupt cancer care and treatment with potentially adverse consequences on survival outcomes. The data support the role of vaccine boosters in preventing severe disease, and further pharmacological intervention to prevent transmission and aid viral clearance to limit disruption of cancer care as the delivery of care continues to evolve during the coronavirus pandemic

Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece

BACKGROUND: Health Related Quality of Life (HRQoL) is an important outcome measure in Inflammatory Bowel Disease (IBD). The aim of our study was to assess HRQoL in a population of 135 Greek patients with IBD. METHODS: A cohort of 135 patients with IBD, 81 with ulcerative colitis (UC) and 54 with Crohn's disease (CD) were enrolled in our study. Demographic and disease-related data were recorded. HRQoL was assessed by a disease-specific and a generic questionnaire, IBDQ and SF-36, respectively. Disease activity was assessed by Harvey-Bradshaw Index and the Colitis Activity Index for CD and UC patients, respectively. RESULTS: Among all variables recorded in our study, only disease activity had a significant effect on HRQoL. Patients with active disease scored significantly lower on both IBDQ and SF-36 when compared to those in remission. Only two among the four IBDQ dimensions, bowel and systemic, had significant ability in distinguishing best patients in remission from those with active disease. CONCLUSIONS: IBD has a negative impact on HRQoL. Patients with active disease are more impaired than patients in remission. In our population of patients bowel and systemic dimensions had a predominant value in patients' perception of quality of life. Patients in our study using the same instrument scored higher than previously reported

Crop Updates 2001 - Weeds

This session covers forty six papers from different authors: 1. INTRODUCTION, Vanessa Stewart, Agriculture Western Australia PLENARY 2. Wild radish – the implications for our rotations, David Bowran, Centre for Cropping Systems INTEGRATED WEED MANAGEMENT IWM system studies/demonstration sites 3. Integrated weed management: Cadoux, Alexandra Wallace, Agriculture Western Australia 4. A system approach to managing resistant ryegrass, Bill Roy, Agricultural Consulting and Research Services Pty Ltd, York 5. Long term herbicide resistance demonstration, Peter Newman, Agriculture Western Australia, Cameron Weeks, Tony Blake and Dave Nicholson 6. Integrated weed management: Katanning, Alexandra Wallace, Agriculture Western Australia 7. Integrated weed management: Merredin, Vanessa Stewart, Agriculture Western Australia 8. Short term pasture phases for weed control, Clinton Revell and Candy Hudson, Agriculture Western Australia Weed biology – implications for IWM 9. Competitivness of wild radish in a wheat-lupin rotation , Abul Hashem, Nerys Wilkins, and Terry Piper, Agriculture Western Australia 10. Population explosion and persistence of wild radish in a wheat-lupin rotation, Abul Hashem, Nerys Wilkins, Aik Cheam and Terry Piper , Agriculture Western Australia 11. Variation is seed dormancy and management of annual ryegrass, Amanda Ellery and Ross Chapman, CSIRO 12. Can we eradicate barley grass, Sally Peltzer, Agriculture Western Australia Adoption and modelling 13. Where to with RIM? Vanessa Stewart1 and Robert Barrett-Lennard2, 1Agriculture Western Australia, 2Western Australian Herbicide Resistance Initiative (WAHRI) 14. Multi-species RIM model, Marta Monjardino1,2, David Pannell2 and Stephen Powles1 1Western Australian Herbicide Resistance Initiative (WAHRI), 2ARE, University of Western Australia 15. What causes WA grain growers to adopt IWM practices? Rick Llewellyn, WAHRI/ARE, Faculty of Agriculture, University of WA New options for IWM? 16. Fuzzy tramlines for more yield and less weeds, Paul Blackwell Agriculture Western Australia, and Maurice Black, Harbour Lights Estate, Geraldton 17. Inter-row knockdowns for profitable lupins, Paul Blackwell, Agriculture Western Australia and Miles Obst, Farmer Mingenew 18. Row cropping and weed control in lupins, Mike Collins and Julie Roche, Agriculture Western Australia 19. Cross seedimg suppresses annual ryegrass and increases wheat yield, Abul Hashem, Dave Nicholson and Nerys Wilkins Agriculture Western Australia 20. Weed control by chaff burial, Mike Collins, Agriculture Western Australia HERBICIDE RESISTANCE 21. Resistance in wild oats to Fop and Dim herbicides in Western Australia, Abul Hashem and Harmohinder Dhammu, Agriculture Western Australia 22. Triazine and diflufenican resistance in wild radish: what it means to the lupin industry, Aik Cheam, Siew Lee, David Nicholson and Peter Newman, Agriculture Western Australia 23. Comparison if in situ v seed testing for determining herbicide resistance, Bill Roy, Agricultural Consulting and Research Services Pty Ltd, York HERBICIDE TOLERANCE 24. Phenoxy herbicide tolerance of wheat, Peter Newman and Dave Nicholson, Agriculture Western Australia 25. Tolerance of wheat to phenoxy herbicides, Harmohinder S. Dhammu, Terry Piper and Mario F. D\u27Antuono, Agriculture Western Australia 26. Herbicide tolerance of new wheats, Harmohinder S. Dhammu, Terry Piper and David F. Nicholson, Agriculture Western Australia 27. Herbicide tolerance of durum wheats, Harmohinder S. Dhammu, Terry Piper and David F. Nicholson, Agriculture Western Australia 28. Herbicide tolerance of new field pea varieties, Harmohinder S. Dhammu, Terry Piper, David F. Nicholson, and Mario F. D\u27Antuono, Agriculture Western Australia 29. Herbicide tolerance of Cooke field peas on marginal soil, Harmohinder S. Dhammu, Terry Piper, David F. Nicholson, and Mario F. D\u27Antuono, Agriculture Western Australia 30. Herbicide tolerance of some annual pasture legumes adapted to coarse textured sandy soils, Clinton Revell and Ian Rose, Agriculture Western Australia 31 Herbicide tolerance of some annual pasture legumes adapted to fine textured clay soils, Clinton Revell and Ian Rose, Agriculture Western Australia WEED CONTROL IN LUCERNE 32. Management of weeds for Lucerne establishment, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 33. Management of weeds in the second year of Lucerne, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 34. Residual effects of weed management in the third year of Lucerne, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 35. Herbicide tolerance and weed control in Lucerne, Peter Newman, Dave Nicholson and Keith Devenish Agriculture Western Australia HERBICIDES – NEW PRODUCTS/PRODUCE USES; USE New products or product use 36. New herbicide options for canola, John Moore and Paul Matson, Agriculture Western Australia 37. Chemical broadleaf weed management in Peaola, Shannon Barraclough and Lionel Martin, Muresk Institute of Agriculture, Curtin University of Technology 38. Balance® - a new broad leaf herbicide for the chickpea industry, Mike Clarke, Jonas Hodgson and Lawrence Price, Aventis CropScience 39. Marshmallow – robust herbicide strategies, Craig Brown, IAMA Agribusiness 40. Affinity DF – a prospective option for selective in-crop marshmallow control, Gordon Cumming, Technical Officer, Crop Care Australasia 41. A new formulation of Carfentrazone-ethyl for pre-seeding knockdown control of broadleaved weeds including Marshmallow, Gordon Cumming, Technical Officer, Crop Care Australasia Herbicide use 42. Autumn applied trifluralin can be effective! Bill Crabtree, Scientific Officer, Western Australian No-Tillage Farmers Association 43. Which knockdown herbicide for small ryegrass? Peter Newman and Dave Nicholson, Agriculture Western Australia 44. Poor radish control with Group D herbicides in lupins, Peter Newman and Dave Nicholson, Agriculture Western Australia WEED ISSUES 45. Distribution and incidence of aphids and barley yellow dwarf virus in over-summering grasses in the WA wheatbelt, Jenny Hawkes and Roger Jones, CLIMA and Agriculture Western Australia 46. e-weed, Vanessa Stewart, Agriculture Western Australia CONTRIBUTING AUTHOR CONTACT DETAIL

rs1004819 Is the Main Disease-Associated IL23R Variant in German Crohn's Disease Patients: Combined Analysis of IL23R, CARD15, and OCTN1/2 Variants

The IL23R gene has been identified as a susceptibility gene for inflammatory bowel disease (IBD) in the North American population. The aim of our study was to test this association in a large German IBD cohort and to elucidate potential interactions with other IBD genes as well as phenotypic consequences of IL23R variants. Genomic DNA from 2670 Caucasian individuals including 833 patients with Crohn's disease (CD), 456 patients with ulcerative colitis (UC), and 1381 healthy unrelated controls was analyzed for 10 IL23R SNPs. Genotyping included the NOD2 variants p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008 and polymorphisms in SLC22A4/OCTN1 (1672 C-->T) and SLC22A5/OCTN2 (-207 G-->C). All IL23R gene variants analyzed displayed highly significant associations with CD. The strongest association was found for the SNP rs1004819 [P = 1.92x10(-11); OR 1.56; 95 % CI (1.37-1.78)]. 93.2% of the rs1004819 TT homozygous carriers as compared to 78% of CC wildtype carriers had ileal involvement [P = 0.004; OR 4.24; CI (1.46-12.34)]. The coding SNP rs11209026 (p.Arg381Gln) was protective for CD [P = 8.04x10(-8); OR 0.43; CI (0.31-0.59)]. Similar, but weaker associations were found in UC. There was no evidence for epistasis between the IL23R gene and the CD susceptibility genes CARD15 and SLC22A4/5. IL23R is an IBD susceptibility gene, but has no epistatic interaction with CARD15 and SLC22A4/5. rs1004819 is the major IL23R variant associated with CD in the German population, while the p.Arg381Gln IL23R variant is a protective marker for CD and UC

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS. Methods In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358. Results Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6–8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64–1·23]). The non-inferiority of anastrozole was established (upper 95% CI <1·25), but its superiority to tamoxifen was not (p=0·49). A total of 69 deaths were recorded (33 for anastrozole vs 36 for tamoxifen; HR 0·93 [95% CI 0·58–1·50], p=0·78), and no specific cause was more common in one group than the other. The number of women reporting any adverse event was similar between anastrozole (1323 women, 91%) and tamoxifen (1379 women, 93%); the side-effect profiles of the two drugs differed, with more fractures, musculoskeletal events, hypercholesterolaemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen. Conclusions No clear efficacy differences were seen between the two treatments. Anastrozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS, which may be be more appropriate for some women with contraindications for tamoxifen. Longer follow-up will be necessary to fully evaluate treatment differences

Evolution of pathogenicity and sexual reproduction in eight Candida genomes

Candida species are the most common cause of opportunistic fungal infection worldwide. Here we report the genome sequences of six Candida species and compare these and related pathogens and non-pathogens. There are significant expansions of cell wall, secreted and transporter gene families in pathogenic species, suggesting adaptations associated with virulence. Large genomic tracts are homozygous in three diploid species, possibly resulting from recent recombination events. Surprisingly, key components of the mating and meiosis pathways are missing from several species. These include major differences at the mating-type loci (MTL); Lodderomyces elongisporus lacks MTL, and components of the a1/2 cell identity determinant were lost in other species, raising questions about how mating and cell types are controlled. Analysis of the CUG leucine-to-serine genetic-code change reveals that 99% of ancestral CUG codons were erased and new ones arose elsewhere. Lastly, we revise the Candida albicans gene catalogue, identifying many new genes.publishe